论文部分内容阅读
目的:研究唾液腺腺样囊性癌(adenoid cystic carcinoma,ACC)中RASSF1A基因的蛋白表达,并分析其与ACC临床病理参数之间的关系。方法:免疫组织化学(immunohistochemistry,IHC)方法分析57例唾液腺ACC和9例瘤旁腺体中RASSF1A基因的蛋白表达,根据染色强度和染色面积对每例病例进行评分,分为0(无)、1(弱)、2(中)、3(强)4个级别。应用SPSS13.0软件包分析RASSF1A蛋白表达与患者性别、年龄、肿瘤部位、组织学分级、分期、复发、转移及患者预后之间的关系。结果:在ACC肿瘤组织的肌上皮和导管上皮的细胞质和细胞核中均见RASSF1A基因的蛋白表达。57例肿瘤组织中,21%(12/57)的病例中无RASSF1A基因的蛋白表达,47%(27/57)的病例中呈弱表达,23%(13/57)呈中度表达,9%(5/57)呈强表达。在瘤旁腺体中,RASSF1A均为强表达。统计学分析显示,RASSF1A基因的蛋白表达与肿瘤的TNM分期呈负相关(P=0.012)。RASSF1A蛋白表达低的患者,生存期显著低于表达高的患者(P=0.035)。结论:RASSF1A基因蛋白表达水平在ACC中下调,并与肿瘤分期及患者的生存期相关,提示RASSF1A基因可作为ACC患者肿瘤发展及预后判断的一个生物学标志物。
Objective: To investigate the protein expression of RASSF1A gene in adenoid cystic carcinoma (ACC) and to analyze its relationship with clinical pathological parameters of ACC. Methods: Immunohistochemistry (IHC) was used to analyze the protein expression of RASSF1A in 57 cases of salivary gland ACC and 9 cases of parathyroid glands. Each case was scored according to the staining intensity and the area of staining. The cases were divided into 0 (none) 1 (weak), 2 (medium), 3 (strong) 4 levels. The relationship between RASSF1A protein expression and patient’s gender, age, tumor location, histological grade, staging, recurrence, metastasis and patient’s prognosis was analyzed by SPSS 13.0 software package. Results: The protein expression of RASSF1A gene was observed in the cytoplasm and nucleus of myoepithelial and ductal epithelium in ACC tumor tissues. Of the 57 tumor tissues, no protein expression of RASSF1A was found in 21% (12/57) of the cases, and 47% (27/57) were weakly expressed, 23% (13/57) were moderately expressed, and 9 % (5/57) was strongly expressed. In the parathyroid gland, RASSF1A are strongly expressed. Statistical analysis showed that the protein expression of RASSF1A gene was negatively correlated with tumor TNM stage (P = 0.012). Patients with low RASSF1A protein expression had significantly lower survival than those with high expression (P = 0.035). CONCLUSIONS: RASSF1A gene protein expression is down-regulated in ACC and correlated with tumor stage and patient’s survival, suggesting that RASSF1A gene may be a biomarker of tumor development and prognosis in patients with ACC.